文献速递贫血与红细胞疾病

羧基麦芽糖铁使用后低磷血症的发生率与预测因素——新加坡单中心3年经验

Incidence and predictors of hypophosphataemia after ferric carboxymaltose use-A 3-year experience from a single institution in Singapore.
PubMed 文献 · Br J Haematol · 2023-07-16

该研究回顾性分析了新加坡单中心2018年8月至2021年8月共1296次羧基麦芽糖铁给药(1069例患者),旨在确定给药后低磷血症发生率及预测因素。结果显示血磷<0.8 mmol/L的发生率为22.7%(n=186),<0.4 mmol/L为1.6%(n=9);作者结论认为羧基麦芽糖糖铁后低磷血症显著,临床医生应谨慎使用。

要点

  • 羧基麦芽糖铁给药后28天内血磷<0.8 mmol/L发生率为22.7%(n=186),<0.4 mmol/L为1.6%(n=9)。

核心结论

  • 羧基麦芽糖铁给药后低磷血症发生显著,临床医生应谨慎使用羧基麦芽糖铁。

研究设计与样本

  • 回顾性审查新加坡单中心2018年8月至2021年8月所有羧基麦芽糖铁给药的去标识化数据。
  • 共纳入1069例患者接受的1296次羧基麦芽糖铁给药,每次给药后28天内评估血红蛋白和血磷水平。

主要发现

  • 给药后28天内血红蛋白平均升高2.45 g/dL(SD=1.94),达峰平均时间6.3天(SD=8.63)。
  • 血磷<0.8 mmol/L发生率为22.7%(n=186),<0.4 mmol/L发生率为1.6%(n=9)。

临床怎么用

  • 作者结论认为羧基麦芽糖铁给药后低磷血症显著,临床医生应谨慎使用羧基麦芽糖铁。

局限性

  • 本研究为单中心回顾性审查。
  • 初期未常规检查血磷水平,实际低磷血症发生率可能更高,本文报告的发生率低于既往荟萃分析报告的数字。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ferric carboxymaltose (FCM) administration helps reduce transfusion requirements in the perioperative situation, which improves patient outcomes and reduces healthcare costs. However, there is increasing evidence of hypophosphataemia after FCM use. We aim to determine the incidence of hypophosphataemia after FCM administration and elucidate potential biochemical factors associated with the development of subsequent hypophosphataemia. A retrospective review of anonymised data of all FCM administrations in a single institution was conducted from August 2018 to August 2021. Each unique FCM dose administered was examined to assess its effect on Hb and serum phosphate levels within the subsequent 28 days from each FCM administration. Phosphate levels were repeatedly measured within the 28-day interval and the lowest phosphate level within that period was determined. Patients' serum phosphate levels within 28 days of FCM administration were compared against normal serum phosphate levels within 2 weeks before FCM administration. The odds ratios of various pre-FCM serum markers were calculated to elucidate potential biochemical predictors of post-FCM hypophosphataemia. In 3 years, a total of 1296 doses of FCM were administered to 1069 patients. The mean improvement in Hb was 2.45 g/dL (SD = 1.94) within 28 days of FCM administration, with the mean time taken to peak Hb levels being 6.3 days (SD = 8.63), which is earlier than expected, but was observed in this study and hence reported. The incidence of hypophosphataemia <0.8 mmol/L was 22.7% (n = 186), and <0.4 mmol/L was 1.6% (n = 9). This figure is lower than the numbers reported in previously published meta-analyses given that routine checks of serum phosphate levels were not conducted initially and hence could possibly be higher. The odds of developing hypophosphataemia (<0.8 mmol/L) were 27.7 (CI: 17.3-44.2, p < 0.0001) if baseline serum phosphate was less than 1 mmol/L. The odds of developing hypophosphataemia (<0.8 mmol/L) were 1.3 (CI: 1.08-1.59, p < 0.01) if the change in Hb levels observed after FCM administration were more than 4 g/dL. Hypophosphataemia after FCM administration is significant and FCM should be used by clinicians with caution.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chu Z, Cushway T, Wong M, et al. Incidence and predictors of hypophosphataemia after ferric carboxymaltose use-A 3-year experience from a single institution in Singapore. Br J Haematol. 2023. PMID: 37455143. doi:10.1111/bjh.18979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。